VERAXA Biotech Receives 99.57% Approval for Merger - Path to NASDAQ Listing Under «VRXA» Cleared

Xlife Sciences AG / CH0461929603

Xlife Sciences AG / Key word(s): IPO/Merger


03.03.2026 / 07:00 CET/CEST

---

Zurich, March 3, 2026: VERAXA Biotech AG («VERAXA»), a portfolio company of Xlife Sciences AG («Xlife Sciences», SIX: XLS) and a leading developer of novel antibody-based cancer therapies, achieved a major milestone at its Extraordinary General Meeting («EGM») on 27 February 2026. Shareholders overwhelmingly approved the merger between VERAXA Biotech AG, Veraxa Biotech Holding AG, and Voyager Acquisition Corp. («Voyager», NASDAQ: VACH).

With 12,680,593 votes - representing 99.57% of the share capital present - the merger was approved, marking an impressive vote of confidence in VERAXA’s strategic development. The transaction will be executed as an absorption merger, under which Veraxa Biotech Holding AG, as the acquiring entity, will integrate VERAXA Biotech AG and subsequently be renamed Veraxa Biotech AG. The existing management team, led by CEO Dr. Christoph Antz, will continue to steer the company’s operations.
Dr. Christoph Antz, CEO of VERAXA Biotech AG, commented: «We are grateful for the strong support of our shareholders. VERAXA is exceptionally well positioned to create long-term value and advance patient-focused, innovative cancer therapies.»
Oliver R. Baumann, CEO of Xlife Sciences AG, added: «The clear approval from shareholders underscores the confidence in VERAXA’s strategic direction and validates our approach of guiding scientifically outstanding platforms toward the capital markets. VERAXA combines strong technology, excellent science, and an experienced management team - the ideal foundation for sustainable success on the international stage.»
Further details on the Extraordinary General Meeting are available on the VERAXA Biotech AG website (link). Following approval by Voyager’s shareholders on 12 March 2026, the merger will be completed and trading will commence shortly thereafter. The information published in this context represents a summary only. Full details can be found in the transaction documents filed with the U.S. Securities and Exchange Commission (SEC) and in Voyager’s proxy statement/prospectus dated 19 February 2026.   Financial calendar

Annual Report 2025	28 April 2026
Annual Shareholders Meeting 2026	26 June 2026
Half-Year Report 2026	24 September 2026

Contact
Information for investors and journalists: Xlife Sciences AG, Dr. Dennis Fink, [e-mail] Xlife Sciences AG, 
Talacker 35, 
8001 Zurich, 
Switzerland,
Phone [phone]
[e-mail], www.xlifesciences.ch, 
Commercial Register Zurich CHE-330.279.788 
Stock Exchange: SIX Swiss Exchange

About Xlife Sciences AG (SIX:XLS) 

Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to the healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development and participates in their subsequent performance. For more information, visit https://www.xlifesciences.ch  About VERAXA Biotech AG

At VERAXA Biotech AG, we strive to establish the premiere drug discovery and development engine for antibody drug conjugates and other novel antibody-based therapy concepts. Wielding a suite of transformative technology innovations and applying thorough quality-by-design principles in drug discovery, we are accelerating our pipeline of antibody drug conjugates and our novel BiTAC antibody formats into and through clinical development. VERAXA Biotech AG originates from scientific discoveries made at the European Molecular Biology Laboratory (EMBL), a world-leading institute for life science research and ground-breaking enabling technologies. For more information, please visit https://www.veraxa.com/  About Voyager Acquistion Corp. (VACH US)

Voyager Acquisition Corp. is a blank check company incorporated in December 2023 as a Cayman Islands exempted company. Headquartered in Brooklyn, New York, its primary objective is to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. Led by experienced professionals with a track record in healthcare and life sciences, Voyager seeks to support transformative businesses on their path to becoming publicly listed companies. For more information, please visit https://www.voyageracq.com/ 

Disclaimer 

Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements.  More information about the Participants in the Solicitation, Non-Solicitation, Forward-Looking Statements and Additional Information can be found in the attached document.

---

End of Media Release
View original content: EQS News

---

Language:	English
Company:	Xlife Sciences AG
	Talacker 35
	8001 Zürich
	Switzerland
Phone:	[phone]
E-mail:	[e-mail]
Internet:	www.xlifesciences.ch
ISIN:	CH0461929603
Valor:	A2PK6Z
Listed:	SIX Swiss Exchange
EQS News ID:	2284236

End of News	EQS News Service

---

2284236  03.03.2026 CET/CEST